Jove
Visualize
Contact Us

Related Experiment Videos

Imiquimod.

G A Richwald1

  • 1Sexually Transmitted Diseases Program, Los Angeles County Department of Health Services, Los Angeles, California, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Imiquimod, an immune modifier, effectively treats genital warts by stimulating the body's own defenses. This therapy offers sustained clearance and is a cost-effective option for HPV infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The communicable disease impact of eliminating publicly funded prenatal care for undocumented immigrants.

Maternal and child health journal·2000
Same author

Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies.

Clinical therapeutics·2000
Same author

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group.

The Journal of infectious diseases·1998
Same author

External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1998
Same author

Comparisons of cost and accuracy of DNA probe test and culture for the detection of Neisseria gonorrhoeae in patients attending public sexually transmitted disease clinics in Los Angeles County.

Sexually transmitted diseases·1997
Same author

The association between Chlamydia trachomatis and ectopic pregnancy. A matched-pair, case-control study.

JAMA·1990
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Immunology
  • Dermatology
  • Virology

Background:

  • Imiquimod is a synthetic immune response modifier used for external genital and perianal warts.
  • It is formulated as a 5% vanishing cream (Aldara) for self-application.
  • Human papillomavirus (HPV) infection causes these warts.

Purpose of the Study:

  • To evaluate the efficacy and safety of imiquimod for treating external genital and perianal warts.
  • To understand the antiviral mechanism of imiquimod.
  • To assess imiquimod's role as a first- or second-line therapy.

Main Methods:

  • Clinical trials assessing efficacy and safety of self-applied imiquimod cream.
  • Preclinical studies (in vitro and in vivo) investigating imiquimod's mechanism of action.

Related Experiment Videos

  • Analysis of post-marketing data on sustained clearance rates.

    • Main Results:

    • Imiquimod demonstrates good efficacy and safety in treating HPV-related warts.
    • Its mechanism involves inducing antiviral and immune-enhancing cytokines, not direct viral action.
    • Patients achieve sustained clearance, outperforming other treatment modalities.
    • Preclinical data show imiquimod induces cytokines from immune cells, potentiating Th1 immunity.

    Conclusions:

    • Imiquimod is a cost-effective first-line therapy for external genital warts due to its unique mechanism, tolerability, and sustained clearance.
    • It serves as an appropriate second-line therapy for recalcitrant cases.
    • Imiquimod shows potential in treating non-HPV skin infections and some dermal neoplasias.